Download PDF
Semin Thromb Hemost 2024; 50(02): 157-168
DOI: 10.1055/s-0043-1775756
Editorial

The Most Highly Cited Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 50 Years in the Making

Emmanuel J. Favaloro 
1   Department of Haematology, Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, Australia
2   School of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, New South Wales, Australia
3   School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
› Author Affiliations
› Further Information
   Permissions and Reprints

Welcome to another editorial relating to our celebration of 50 years of publishing for Seminars in Thrombosis & Hemostasis (STH). As noted several times previously, 2024 marks the 50th birthday of STH, which first published in 1974.[1] A half-century of publishing is a landmark worthy of celebration. We started the celebrations in 2022, when we published our first 50th year celebratory issue.[2] A second celebratory issue was published in 2023,[3] and a third compilation was published as the first issue of 2024.[4] All issues were rich in content of a historical nature related to the fields of thrombosis and hemostasis. We plan to prepare a 4th and final 50th year celebratory compilation later in this year. In the interim, we plan to publish a separate tribute to the rich history of STH in each issue of STH publishing in 2024. For the first issue of 2024, we republished the first paper ever published in STH, on the molecular structure of fibrinogen,[5] together with an accompanying commentary from Neerman-Arbez and Casini.[6] In the next few issues of STH, we will republish the most highly cited publications from STH of all time, as also accompanied by commentaries from experts in these specific featured fields.

This editorial is accompanying the second issue of STH for 2024 and provides two tables that outline the most highly cited papers from STH. [Table 1] identifies the 100 manuscripts that have been most highly cited over the entire publication history of STH, starting from the first paper published in 1974.[5] These papers have a citation count of 119 or more. Naturally, in such a listing, papers published earlier in the STH publication timeline have considerable advantage in terms of overall citations compared to more recent publications. However, this is still an important analysis for our journal. I would like to make a few comments on this listing. First, three of the papers on the top 100 list were authored by the founding editor in chief of STH, Eberhard F. Mammen. This included two papers on the platelet function analyzer (PFA)-100.[7] [8] It is likely that these papers helped the manufacturer obtain regulatory approvals for clinical use of the PFA-100 in hemostasis laboratories. Another paper on the PFA-100, the first full report to describe the instrument,[9] is understandably also a highly cited paper, listing third on the table. Another paper on the PFA-100 in [Table 1] is my own contribution,[10] written as a tribute to Eberhard Mammen, following his passing in 2008.[11] [12] STH has published several more recent publications mentioning the PFA-100, including its recent remodeling as the PFA-200.[13] [14] [15]

Table 1

The 100 most highly cited papers from Seminars in Thrombosis and Hemostasis of all time[a]

Rank

Citation

Publication year

1

Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost. 2003 Oct;29(5):435–450.

2003

2

Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990 Jan;16(1):1–20.

1990

3

Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer–PFA-100. Semin Thromb Hemost. 1995;21 Suppl 2:106–112.

1995

4[b]

Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24(2):195–202.

1998

5

Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:5–16.

1999

6

Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005;31(4):381–392.

2005

7

Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004 Oct;30(5):579–589.

2004

8

Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125–130.

2003

9

Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17 Suppl 3:304–312.

1991

10

Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the Tumor Vasculature. Semin Thromb Hemost. 2010 Apr;36(3):321–331.

2010

11

Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost. 2000;26(3):219–225.

2000

12

Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 Apr;31(2):174–183.

2005

13[b]

Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, Selik NR, Wilson RF. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost. 1985 Jul;11(3):281–292.

1985

14

Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23(4):349–356.

1997

15

Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, Gries FA. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991 Oct;17(4):433–438.

1991

16

Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004 Feb;30(1):95–108.

2004

17

Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991 Jul;17(3):303–312.

1991

18

Tracy PB. Regulation of thrombin generation at cell surfaces. Semin Thromb Hemost. 1988 Jul;14(3):227–233.

1988

19[c]

Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost. 2008 Nov;34(8):709–733.

2008

20

van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005 Apr;31(2):195–204.

2005

21

Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005 Apr;31(2):184–194.

2005

22

Østerud B, Bjørklid E. Sources of tissue factor. Semin Thromb Hemost. 2006 Feb;32(1):11–23.

2006

23

Rak J. Microparticles in cancer. Semin Thromb Hemost. 2010 Nov;36(8):888–906.

2010

24

Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25 Suppl 2:15–19.

1999

25

Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006 Apr;32 Suppl 1:49–60.

2006

26

Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost. 1998;24(1):33–44.

1998

27

Bachmann F, Kruithof IE. Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost. 1984 Jan;10(1):6–17.

1984

28

Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006 Apr;32 Suppl 1:3–15.

2006

29

Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25(2):173–182.

1999

30

Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost. 1992;18(4):353–372.

1992

31

Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet Physiology. Semin Thromb Hemost. 2016 Apr;42(3):191–204.

2016

32

Walker FJ. Protein S and the regulation of activated protein C. Semin Thromb Hemost. 1984 Apr;10(2):131–138.

1984

33

de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013 Sep;39(6):585–595.

2013

34

Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost. 1992 Jan;18(1):104–116.

1992

35

Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990 Jul;16(3):207-216.

1990

36

Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost. 2010 Nov;36(8):807–818.

2010

37

Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008 Apr;34(3):236–250.

2008

38

Kelton JG, Gibbons S. Autoimmune platelet destruction: idiopathic thrombocytopenic purpura. Semin Thromb Hemost. 1982 Apr;8(2):83–104.

1982

39

Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007 Jun;33(4):313–320.

2007

40

Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost. 1978 Summer;5(1):1–26.

1978

41

Bick RL. Disseminated intravascular coagulation and related syndromes: a clinical review. Semin Thromb Hemost. 1988 Oct;14(4):299–338.

1988

42

Dentali F, Sironi AP, Ageno W, Turato S, Bonfanti C, Frattini F, Crestani S, Franchini M. Non-O Blood Type Is the Commonest Genetic Risk Factor for VTE: Results from a Meta-Analysis of the Literature. Semin Thromb Hemost. 2012 Jul;38(5):535–548.

2012

43

Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999;25 Suppl 2:25–28.

1999

44

De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost. 1998;24(4):367–379.

1998

45

Goldfarb RH, Liotta LA. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost. 1986 Oct;12(4):294–307.

1986

46

Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII Deficiency. Semin Thromb Hemost. 2009 Jun;35(4):426–438.

2009

47

Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2014 Apr;40(3):277–283.

2014

48

Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost. 2005 Apr;31(2):217–233.

2005

49

Bick RL. Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost. 1985 Jul;11(3):249–280.

1985

50

Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost. 2020 Oct;46(7):763–771.

2020

51

Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost. 1990 Oct;16(4):299–309.

1990

52

Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost. 2002 Dec;28(6):555–568.

2002

53

Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost. 2000;26(3):341–348.

2000

54

Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost. 2009 Mar;35(2):189–203.

2009

55

Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost. 1987 Jan;13(1):50–68.

1987

56

Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost. 1984 Jan;10(1):24–41.

1984

57

Bevilacqua MP, Gimbrone MA Jr. Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost. 1987 Oct;13(4):425–433.

1987

58[b]

Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost. 1995;21 Suppl 2:113–121.

1995

59

Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86–93.

2019

60

Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost. 2010 Feb;36(1):59–70.

2010

61

Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost. 2006 Apr;32 Suppl 1:61–68.

2006

62

Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost. 2010 Feb;36(1):34–40.

2010

63

Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost. 1999;25(2):137–145.

1999

64

Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost. 2018 Feb;44(1):20–29.

2018

65

Bick RL. Clinical relevance of antithrombin III. Semin Thromb Hemost. 1982 Oct;8(4):276–287.

1982

66

Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost. 1992;18(4):392–415.

1992

67

Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost. 2012 Sep;38(6):565–575.

2012

68

Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost. 1997;23(4):339–347.

1997

69

Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost. 2009 Mar;35(2):158–167.

2009

70

Mariani G, Bernardi F. Factor VII Deficiency. Semin Thromb Hemost. 2009 Jun;35(4):400–406.

2009

71

Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost. 2003 Oct;29(5):467–471.

2003

72

Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost. 2000;26(5):561–569.

2000

73

Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013 Jul;39(5):559–566.

2013

74

Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost. 2012 Feb;38(1):102–113.

2012

75

Hermans J, McDonagh J. Fibrin: structure and interactions. Semin Thromb Hemost. 1982 Jan;8(1):11–24.

1982

76

Leroy J, Leclerc MH, Delahousse B, Guérois C, Foloppe P, Gruel Y, Toulemonde F. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost. 1985 Jul;11(3):326–329.

1985

77

Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost. 2008 Oct;34(7):612–634.

2008

78

Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost. 1989 Jul;15(3):269-282.

1989

79

Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost. 2006 Apr;32 Suppl 1:32–38.

2006

80

Østerud B, Bjørklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost. 2001 Dec;27(6):605–617.

2001

81

Bukowski RM, Hewlett JS, Reimer RR, Groppe CW, Weick JK, Livingston RB. Therapy of thrombotic thrombocytopenic purpura: an overview. Semin Thromb Hemost. 1981 Winter;7(1):1–8.

1981

82

Griffin JH, Cochrane CG. Recent advances in the understanding of contact activation reactions. Semin Thromb Hemost. 1979 Spring;5(4):254–273.

1979

83

Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost. 2002 Jun;28 Suppl 2:3–13.

2002

84

Isbister GK. Snakebite doesn't cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming. Semin Thromb Hemost. 2010 Jun;36(4):444–451.

2010

85

Markus G. The role of hemostasis and fibrinolysis in the metastatic spread of cancer. Semin Thromb Hemost. 1984 Jan;10(1):61–70.

1984

86

Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost. 2002 Feb;28(1):53–66.

2002

87

Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost. 1998;24(2):93–109.

1998

88

Olson ST, Björk I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost. 1994;20(4):373–409.

1994

89

Coppola A, Davi G, De Stefano V, Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost. 2000;26(3):243–254.

2000

90

De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23(5):411–418.

1997

91

Chandler WL. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost. 1995;21 Suppl 4:1–6.

1995

92

Ferro V, Dredge K, Liu L, Hammond E, Bytheway I, Li C, Johnstone K, Karoli T, Davis K, Copeman E, Gautam A. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost. 2007 Jul;33(5):557–568.

2007

93

van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost. 2000;26(3):281–289.

2000

94

Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost. 1989 Jan;15(1):58–87.

1989

95

Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost. 2001 Dec;27(6):585–592.

2001

96

Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost. 2006 Nov;32(8):803–809.

2006

97

Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005 Feb;31(1):104–110.

2005

98

Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost. 2000;26 Suppl 1:5–21.

2000

99

Franceschi LD, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011 Apr;37(3):226–236.

2011

100

Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, Kogan PW, Kogan TP, McKinney AA, Schwarz RP Jr. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997;23(6):503–516.

1997

a From the first publication in 1974,[5] to the date of data compilation (August 5, 2023). Data from Web of Science. The papers on this list have been cited 119 or more times since publication.


b Authored by founding editor in chief of STH.


c Authored by current editor in chief of STH as a tribute to founding editor in chief of STH, after his passing in 2008.


However, the most highly cited paper from STH is on the topic of blood rheology and hemodynamics, from the authorship team of Baskurt and Meiselman.[16] In the preparation of this editorial, I learnt that Prof Baskurt unfortunately passed away in 2013, and an In Memoriam was fittingly prepared by his colleague Prof Meiselman.[17] Prof Meiselman is still professionally active and has agreed to coauthor a commentary to accompany the republication of his original paper.[16]

The second most highly cited paper from STH is on the topic of skin bleeding time, from the authorship team of Rodgers and Levin.[18] In the preparation for this editorial, I discovered that Prof Levin is still professionally active and has agreed to coauthor a commentary to accompany the republication of his original paper.[18] It is also interesting to me that the skin bleeding time, an invasive procedure requiring the patient to be subjected to a skin cut, was in part replaced by the PFA-100, which in several papers has been described as an in vitro bleeding time. Thus, three of the four papers heading the list in [Table 1] can be considered as “somewhat related.”[7] [9] [18]

It is also interesting to me that these papers are still being cited in the current literature. [Fig. 1] provides a summary of citations for the four leading papers in [Table 1]. Impressively, the leading paper[16] is being cited more currently than it was in the past, suggesting continued high relevance in 2024! One could say it was way ahead of its time.

Zoom Image
Fig. 1 Citations over time for the four most highly cited papers from [Table 1]. Data shown in 5-year groupings, with the year of publication for each paper also noted at the start of each data curve. Data from Web of Science. Data compiled up to the date of data collection (August 5th, 2023); thus, the period 2020 to 2024 comprises less than 4 years of data.

The most “prolific” author on the list in [Table 1] is Roger L. Bick, with five papers listed. According to PubMed, Prof Bick published 163 papers during his career, with 34 of these appearing in STH, the first of which appeared in STH in 1976, only 2 years after STH began. So, Prof Bick was a strong supporter of this journal during his professional life. In comparison, also according to PubMed, Eberhard Mammen is attributed with 119 publications, with 15 of these appearing in STH, the first of which published in 1975. Like Eberhard Mammen, Roger Bick also passed away too young in 2008.[19] [20]

In the top 10 most highly cited papers ([Table 1]) is a paper from Jurk and Kehrel, on the physiology and biochemistry of platelets.[21] This is a perennial favorite of STH readers and is always on the top list of most downloaded papers in every year of analysis, as well as being an almost permanent fixture in the “most read” list in the online journal list of top 10.[22] And, yes, it was on this list at time of writing this editorial. The continued popularity of this paper actually led me to commission an update, which was written by Gremmel et al[23] and which also appears on the top 100 list ([Table 1]), as well as on the online journal list of top 10.[22]

Of course, not all the papers appearing on the top 100 cited papers of all time are from the historical vault of STH, with several published in the last two decades. To highlight these recent most highly cited papers, I have provided a separate table ([Table 2]) that lists the most highly cited papers from STH according to the yearly citation rate. The papers on this list have been cited eight or more times per year on average since publication. Most papers are from the past two decades, indicating the continued relevance of STH in the current thrombosis and hemostasis literature. Quite a few of these papers relate to coronavirus disease 2019 (COVID-19), including the paper with the highest yearly citation rate by Di Minno et al.[24] This paper has been cited 141 times since publishing, for an annual citation rate of nearly 38 citations/year for 2020 to 2023 inclusive. COVID-19 is a terrible disease but somehow unified humanity to aim to understand, treat, and combat the disease. STH published four issues devoted to COVID-19 over the years 2020 to 2023,[25] [26] [27] [28] and the content in these issues proved very popular with the readership,[29] [30] [31] as well as being highly cited ([Table 2]).

Table 2

The 100 most highly cited papers from Seminars in Thrombosis and Hemostasis in terms of yearly citations[a]

Rank

Citation

Publication year

1

Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost. 2020 Oct;46(7):763–771.

2020

2

Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost. 2003 Oct;29(5):435–450.

2003

3

Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86–93.

2019

4

Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost. 2018 Feb;44(1):20–29.

2018

5

Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet physiology. Semin Thromb Hemost. 2016 Apr;42(3):191–204.

2016

6

Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost. 2019 Oct;45(7):661–673.

2019

7

Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost. 2020 Feb;46(1):89–95.

2020

8

Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010 Apr;36(3):321-331.

2010

9

Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism? Semin Thromb Hemost. 2020 Oct;46(7):777–780.

2020

10

Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005;31(4):381–392.

2005

11

Favaloro EJ, Henry BM, Lippi G. Increased VWF and Decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost. 2021 Jun;47(4):400–418.

2021

12

de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013 Sep;39(6):585–595.

2013

13

Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb Hemost. 2020 Oct;46(7):781–784.

2020

14

Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2014 Apr;40(3):277–283.

2014

15

Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004 Oct;30(5):579–589.

2004

16

Rak J. Microparticles in cancer. Semin Thromb Hemost. 2010 Nov;36(8):888–906.

2010

17

Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990 Jan;16(1):1–20.

1990

18

Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer–PFA-100. Semin Thromb Hemost. 1995;21 Suppl 2:106–112.

1995

19

Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost. 2008 Nov;34(8):709–733.

2008

20

Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost. 2021 Jun;47(4):362–371.

2021

21

Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost. 2019 Jun;45(4):385–395.

2019

22

Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost. 2021 Jun;47(4):372–391.

2021

23

Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24(2):195–202.

1998

24

Agersnap I, Nissen PH, Hvas AM. The role of plasminogen activator inhibitor type 1 (PAI-1) in placenta-mediated pregnancy complications: a systematic review. Semin Thromb Hemost. 2022 Jul;48(5):607–624.

2017

25

Dentali F, Sironi AP, Ageno W, Turato S, Bonfanti C, Frattini F, Crestani S, Franchini M. Non-O blood type is the commonest genetic risk factor for vte: results from a meta-analysis of the literature. Semin Thromb Hemost. 2012 Jul;38(5):535–548.

2012

26

Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 Apr;31(2):174–183.

2005

27

Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125–130.

2003

28

Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:5–16.

1999

29

Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013 Jul;39(5):559–566.

2013

30

Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004 Feb;30(1):95–108.

2004

31

Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. Semin Thromb Hemost. 2019 Jun;45(4):413–422.

2019

32

Lacroix R, Robert S, Poncelet P, Dignat-George F. Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost. 2010 Nov;36(8):807–818.

2010

33

Crous-Bou M, Harrington LB, Kabrhel C. Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemost. 2016 Nov;42(8):808–820.

2016

34

Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost. 2012 Sep;38(6):565–575.

2012

35

Østerud B, Bjørklid E. Sources of tissue factor. Semin Thromb Hemost. 2006 Feb;32(1):11–23.

2006

36

van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005 Apr;31(2):195–204.

2005

37

Favaloro EJ, Lippi G. Recommendations for minimal laboratory testing panels in patients with COVID-19: potential for prognostic monitoring. Semin Thromb Hemost. 2020 Apr;46(3):379–382.

2020

38

Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006 Apr;32 Suppl 1:49–60.

2006

39

Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost. 2012 Feb;38(1):102–113.

2012

40

Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005 Apr;31(2):184–194.

2005

41

Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelet-cancer interactions. Semin Thromb Hemost. 2014 Apr;40(3):296–305

2014

42

Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost. 2000;26(3):219-225.

2000

43

Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost. 2006 Apr;32 Suppl 1:3–15.

2006

44

Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost. 2017 Apr;43(3):331–337.

2017

45

Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013 Sep;39(6):621–631.

2013

46

Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost. 2009 Jun;35(4):426–438.

2009

47

Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation. Semin Thromb Hemost. 2015 Jul;41(5):527–537.

2015

48

Levi M, Poll TV. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015 Feb;41(1):9–15.

2015

49

Onorato D, Pucci M, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in European and North American Patients Infected with COVID-19: a meta-analysis. Semin Thromb Hemost. 2021 Jun;47(4):392–399.

2021

50

Pierangeli SS, Chen PP, Raschi E, Scurati S, Grossi C, Borghi MO, Palomo I, Harris EN, Meroni PL. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008 Apr;34(3):236–250.

2008

51

Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. Semin Thromb Hemost. 2010 Feb;36(1):59–70.

2010

52

Jalal DI, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost. 2010 Feb;36(1):34–40.

2010

53

de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. Impaired breakdown of bradykinin and its metabolites as a possible cause for pulmonary edema in COVID-19 infection. Semin Thromb Hemost. 2020 Oct;46(7):835–837.

2020

54

Althaus K, Greinacher A. MYH9-related platelet disorders. Semin Thromb Hemost. 2009 Mar;35(2):189–203.

2009

55

Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016 Jun;42(4):366–374.

2016

56

Litvinov RI, Weisel JW. What is the biological and clinical relevance of fibrin? Semin Thromb Hemost. 2016 Jun;42(4):333–343

2016

57

Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost. 2014 Jun;40(4):444–464.

2014

58

Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007 Jun;33(4):313–320.

2007

59

Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost. 2017 Sep;43(6):562–571.

2017

60

Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-a multifaceted serpin. Semin Thromb Hemost. 2013 Jun;39(4):356–364.

2013

61

Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of Atypical Hemolytic Uremic Syndrome (aHUS). Semin Thromb Hemost. 2014 Jun;40(4):422–430.

2014

62

Favaloro EJ, Franchini M, Lippi G. Aging hemostasis: changes to laboratory markers of hemostasis as we age—a narrative review. Semin Thromb Hemost. 2014 Sep;40(6):621–633.

2014

63

McEwen BJ. The influence of diet and nutrients on platelet function. Semin Thromb Hemost. 2014 Mar;40(2):214–226.

2014

64

Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost. 2009 Mar;35(2):158–167.

2009

65

Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost. 2020 Apr;46(3):302–319.

2020

66

Schroeder V, Kohler HP. Factor XIII: structure and function. Semin Thromb Hemost. 2016 Jun;42(4):422–428.

2016

67

Schulman S. Coronavirus Disease 2019, Prothrombotic factors, and venous thromboembolism. Semin Thromb Hemost. 2020 Oct;46(7):772–776.

2020

68

Isbister GK. Snakebite doesn't cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming. Semin Thromb Hemost. 2010 Jun;36(4):444–451.

2010

69

Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost. 2009 Jun;35(4):400–406.

2009

70

Lippi G, Favaloro EJ. Venous and arterial thromboses: two sides of the same coin? Semin Thromb Hemost. 2018 Apr;44(3):239–248.

2018

71

Franceschi LD, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011 Apr;37(3):226–236.

2011

72

Semeraro N, Ammollo CT, Semeraro F, Colucci M. Coagulopathy of acute sepsis. Semin Thromb Hemost. 2015 Sep;41(6):650–658.

2015

73

Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost. 2014 Mar;40(2):163–171.

2014

74

Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23(4):349–356.

1997

75

Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost. 2019 Feb;45(1):22–35.

2019

76

Federici AB, Budde U, Castaman G, Rand JH, Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013 Mar;39(2):191–201.

2013

77

Naudin C, Burillo E, Blankenberg S, Butler L, Renné T. Factor XII Contact Activation. Semin Thromb Hemost. 2017 Nov;43(8):814–826.

2017

78

Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost. 2013 Apr;39(3):258–266.

2013

79

Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: an update. Semin Thromb Hemost. 2019 Jun;45(4):321–325.

2019

80

Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost. 2017 Apr;43(3):277–290.

2017

81

Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin k antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost. 2015 Mar;41(2):208–227.

2015

82

Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost. 2011 Nov;37(8):903–907.

2011

83

Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. Semin Thromb Hemost. 2017 Jun;43(4):386–396.

2017

84

Johansen ME, Johansson PI, Ostrowski SR, Bestle MH, Hein L, Jensen AL, Søe-Jensen P, Andersen MH, Steensen M, Mohr T, Thormar K, Lundgren B, Cozzi-Lepri A, Lundgren JD, Jensen JU. Profound endothelial damage predicts impending organ failure and death in sepsis. Semin Thromb Hemost. 2015 Feb;41(1):16–25

2015

85

Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost. 2014 Feb;40(1):106–114.

2014

86

Dahlbäck B. Vitamin K-dependent protein s: beyond the protein C pathway. Semin Thromb Hemost. 2018 Mar;44(2):176–184.

2018

87

Ramström S, Södergren AL, Tynngård N, Lindahl TL. Platelet function determined by flow cytometry: new perspectives? Semin Thromb Hemost. 2016 Apr;42(3):268–281.

2016

88

Draxler DF, Sashindranath M, Medcalf RL. Plasmin: a modulator of immune function. Semin Thromb Hemost. 2017 Mar;43(2):143–153

2017

89

Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17 Suppl 3:304–312.

1991

90

Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost. 2005 Apr;31(2):217–233.

2005

91

Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost. 1999;25 Suppl 2:15–19.

1999

92

Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost. 2008 Oct;34(7):612–634.

2008

93

Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost. 2020 Apr;46(3):275–288.

2020

94

Dorgalaleh A. Bleeding and bleeding risk in COVID-19. Semin Thromb Hemost. 2020 Oct;46(7):815–818.

2020

95

Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost. 2016 Jun;42(4):356–365.

2016

96

de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010 Feb;36(1):7–17.

2010

97

DeLoughery EP, Olson SR, Puy C, McCarty OJT, Shatzel JJ. The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials. Semin Thromb Hemost. 2019 Jul;45(5):502–508.

2019

98

Rondon AMR, Kroone C, Kapteijn MY, Versteeg HH, Buijs JT. Role of tissue factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost. 2019 Jun;45(4):396–412.

2019

99

Amabile N, Rautou PE, Tedgui A, Boulanger CM. Microparticles: key protagonists in cardiovascular disorders. Semin Thromb Hemost. 2010 Nov;36(8):907–916.

2010

100

Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost. 2012 Sep;38(6):576–585.

2012

a Data from Web of Science (compiled up to the date of data collection; August 5, 2023). The papers on this list have been cited an average of 8 or more times per year since publication.


Also on this list in [Table 2] are several of the papers from [Table 1], highlighting that these appear in [Table 1], not because their citations reflect an accumulation of historical papers from the distant past, but because they have proven consistently relevant over time. In any case, we look forward to continuing to publish material of interest to our readership for the next 50 years!



Publication History

Article published online:
27 September 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA